CADM2 inhibits human glioma proliferation, migration and invasion

Liu,Nan; Yang,Chen; Bai,Wansheng; Wang,Zhen; Wang,Xin; Johnson,Mark; Wang,Wenshi; Zhang,Pengxing; Yang,Hongwei; Liu,Hui; Cheng,Yingduan; Tu,Yanyang

doi:10.3892/or.2019.7010

CADM2 inhibits human glioma proliferation, migration and invasion

Authors:
- Nan Liu
- Chen Yang
- Wansheng Bai
- Zhen Wang
- Xin Wang
- Mark Johnson
- Wenshi Wang
- Pengxing Zhang
- Hongwei Yang
- Hui Liu
- Yingduan Cheng
- Yanyang Tu
View Affiliations

Affiliations: Department of Experimental Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China, Postdoctoral Research Station of Neurosurgery, Wuhan General Hospital of Guangzhou Command, The People's Liberation Army, Wuhan, Hubei 430064, P.R. China, Department of Neurosurgery, 323rd Hospital of The People's Liberation Army, Xi'an, Shaanxi 710054, P.R. China, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA, Department of Neurosurgery, University of Massachusetts Medical School, Worcester, MA 01605, USA, HemaCare, Van Nuys, CA 91406, USA
Published online on: February 13, 2019 https://doi.org/10.3892/or.2019.7010
Pages: 2273-2280

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant glioma is one of the most common malignant tumors in the brain parenchyma with a poor prognosis. Cell adhesion molecules (CADMs) immunoglobulin super family is involved in the maintenance of cell adhesion, polarity and tumor suppression. However, the role and mechanisms of CADM2 in human glioma have yet to be elucidated. Therefore, the present study evaluated the expression level of CADM2 and demonstrated that CADM2 was markedly downregulated in human glioma tissues compared with normal brain tissue and glioma cell lines, and the CADM2 expression level was significantly decreased in high‑grade glioma tissues. Overexpression of CADM2 inhibited the proliferation of glioma cell proliferation in vitro and in vivo. CADM2 also inhibited the migration and invasion of U87 and U251 cells. Furthermore, overexpression of CADM2 induced a significant decrease in the expression of G1/S transition key regulators, cyclin D1, cyclin E, cyclin‑dependent kinase (CDK)2 and CDK4. Additionally, CADM2 expression was associated with alterations in epithelial‑mesenchymal transition (EMT) markers, including E‑cadherin and β‑catenin. Taken together, the results of the present study demonstrated that CADM2 inhibits glioma tumorigenesis by regulating the cell cycle and the EMT process, suggesting that CADM2 may be a novel potential therapeutic target in human glioma.

View Figures

View References

1	Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, et al: Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 26:756–784. 2012. View Article : Google Scholar : PubMed/NCBI
2	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
3	Oike T, Suzuki Y, Sugawara K, Shirai K, Noda SE, Tamaki T, Nagaishi M, Yokoo H, Nakazato Y and Nakano T: Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results. PLoS One. 8:e789432013. View Article : Google Scholar : PubMed/NCBI
4	Fiorica F, Carau B, Ursino S and Cartei F: Radiotherapy plus concomitant and adjuvant temozolomide for unresectable glioblastoma: A retrospective analysis of our experience. Radiother Oncol. 81:S297. 2006.
5	Hargreaves SJ, Williams M, Liu Z, et al: Survival in patients receiving radiotherapy plus concomitant and adjuvant temozolomide (RCAT) for glioblastoma (GBM). Int J Radiat Oncol Biol Phys. 78:S281–S282. 2010. View Article : Google Scholar
6	He W, Li X, Xu S, Ai J, Gong Y, Gregg JL, Guan R, Qiu W, Xin D, Gingrich JR, et al: Aberrant methylation and loss of CADM2 tumor suppressor expression is associated with human renal cell carcinoma tumor progression. Biochem Biophys Res Commun. 435:526–532. 2013. View Article : Google Scholar : PubMed/NCBI
7	Yang S, Yan HL, Tao QF, Yuan SX, Tang GN, Yang Y, Wang LL, Zhang YL, Sun SH and Zhou WP: Low CADM2 expression predicts high recurrence risk of hepatocellular carcinoma patients after hepatectomy. J Cancer Res Clin Oncol. 140:109–116. 2014. View Article : Google Scholar : PubMed/NCBI
8	Takai Y, Irie K, Shimizu K, Sakisaka T and Ikeda W: Nectins and nectin-like molecules: Roles in cell adhesion, migration, and polarization. Cancer Sci. 94:655–667. 2003. View Article : Google Scholar : PubMed/NCBI
9	Murakami Y: Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis. Cancer Sci. 96:543–552. 2005. View Article : Google Scholar : PubMed/NCBI
10	Chang GM, Xu SP, Dhir R, Chandran U, O'Keefe DS, Greenberg NM and Gingrich JR: Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer. Clin Cancer Res. 16:5390–5401. 2010. View Article : Google Scholar : PubMed/NCBI
11	Cody NA, Shen Z, Ripeau JS, Provencher DM, Mes-Masson AM, Chevrette M and Tonin PN: Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian Cancer cell line model genetically modified by chromosome 3 fragment transfer. Mol Carcinog. 48:1077–1092. 2009. View Article : Google Scholar : PubMed/NCBI
12	Lake SL, Coupland SE, Taktak AF and Damato BE: Whole-genome microarray detects deletions and loss of heterozygosity of chromosome 3 occurring exclusively in metastasizing uveal melanoma. Invest Ophthalmol Vis Sci. 51:4884–4891. 2010. View Article : Google Scholar : PubMed/NCBI
13	Roy D, Sin SH, Damania B and Dittmer DP: Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines. Blood. 118:e32–e39. 2011. View Article : Google Scholar : PubMed/NCBI
14	Tu YY, Gao XC, Li G, Fu H, Cui D, Liu H, Jin W and Zhang Y: MicroRNA-218 inhibits glioma invasion, migration, proliferation, and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1. Cancer Res. 73:6046–6055. 2013. View Article : Google Scholar : PubMed/NCBI
15	Allen M, Bjerke M, Edlund H, Nelander S and Westermark B: Origin of the U87MG glioma cell line: Good news and bad news. Sci Transl Med. 8:354re32016. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Micalizzi DS, Farabaugh SM and Ford HL: Epithelial-mesenchymal transition in cancer: Parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 15:117–134. 2010. View Article : Google Scholar : PubMed/NCBI
18	Lee MY, Chou CY, Tang MJ and Shen MR: Epithelial mesenchymal transition in cervical cancer: Correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation. Clin Cancer Res. 14:47–43. 2008. View Article : Google Scholar
19	Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, Maruyama T, Ghosh HP, Pletcher M, Isomura M, Onizuka M, Kitamura T, et al: TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet. 27:427–430. 2001. View Article : Google Scholar : PubMed/NCBI
20	Fukuhara H, Kuramochi M, Fukami T, Kasahara K, Furuhata M, Nobukuni T, Maruyama T, Isogai K, Sekiya T, Shuin T, et al: Promoter methylation of TSLC1 and tumor suppression by its gene product in human prostate cancer. Jap J Cancer Res. 93:605–609. 2002. View Article : Google Scholar
21	Ito T, Shimada Y, Hashimoto Y, Kaganoi J, Kan T, Watanabe G, Murakami Y and Imamura M: Involvement of TSLC1 in progression of esophageal squamous cell carcinoma. Cancer Res. 63:6320–6326. 2003.PubMed/NCBI
22	Takahashi Y, Iwai M, Kawai T, Arakawa A, Ito T, Sakurai-Yageta M, Ito A, Goto A, Saito M, Kasumi F, et al: Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer. Breast Cancer. 19:242–252. 2012. View Article : Google Scholar : PubMed/NCBI
23	Williams YN, Masuda M, Sakurai-Yageta M, Maruyama T, Shibuya M and Murakami Y: Cell adhesion and prostate tumor-suppressor activity of TSLL2/IGSF4C, an immunoglobulin superfamily molecule homologous to TSLC1/IGSF4. Oncogene. 25:1446–1453. 2006. View Article : Google Scholar : PubMed/NCBI
24	Raveh S, Gavert N, Spiegel I and Ben-Ze'ev A: The cell adhesion nectin-like molecules (Necl) 1 and 4 suppress the growth and tumorigenic ability of colon cancer cells. J Cell Biochem. 108:326–36. 2009. View Article : Google Scholar : PubMed/NCBI
25	Nagata M, Sakurai-Yageta M, Yamada D, Goto A, Ito A, Fukuhara H, Kume H, Morikawa T, Fukayama M, Homma Y, et al: Aberrations of a cell adhesion molecule CADM4 in renal clear cell carcinoma. Int J Cancer. 130:1329–1337. 2012. View Article : Google Scholar : PubMed/NCBI